:
Inflammatory bowel disease (IBD) is a general term for a group of chronic and progressive disorders.
Several cellular and biomolecular pathways are implicated in the pathogenesis of IBD, yet the etiology is unclear.
Activation of the mammalian target of rapamycin (mTOR) pathway in the intestinal epithelial cells was also shown
to induce inflammation. This review focuses on the inhibition of the mTOR signaling pathway and its potential
application in treating IBD. We also provide an overview on plant-derived compounds that are beneficial for the
IBD management through modulation of the mTOR pathway. Data were extracted from clinical, in vitro and in vivo
studies published in English between 1995 and May 2019, which were collected from PubMed, Google Scholar,
Scopus and Cochrane library databases. Results of various studies implied that inhibition of the mTOR signaling
pathway downregulates the inflammatory processes and cytokines involved in IBD. In this context, a number of
natural products might reverse the pathological features of the disease. Furthermore, mTOR provides a novel drug
target for IBD. Comprehensive clinical studies are required to confirm the efficacy of mTOR inhibitors in treating
IBD.
Downregulation of microRNA‑124‑3p suppresses the mTOR signaling pathway by targeting DDIT4 in males with major depressive disorder
